WallStSmart
PTCT

PTC Therapeutics Inc

NASDAQ: PTCT · HEALTHCARE · BIOTECHNOLOGY

$64.55
-8.13% today

Updated 2026-04-29

Market cap
$5.83B
P/E ratio
8.19
P/S ratio
3.37x
EPS (TTM)
$8.58
Dividend yield
52W range
$36 – $88
Volume
1.2M

WallStSmart proprietary scores

45
out of 100
Grade: C
Sell
Investment rating
5.3
Growth
C+
5.3
Quality
C+
6.0
Profitability
B
8.7
Valuation
A
5/9
Piotroski F-Score
Moderate
0.2
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target
$87.93
+36.22%
12-Month target
$64.52
-0.05%
Intrinsic (DCF)
$89.55
Margin of safety
+20.80%
3 Strong Buy5 Buy5 Hold1 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Profit margin 39.40% — above average
+ 20.80% below intrinsic value
Risks
- Altman Z 0.22 — distress zone
- Negative free cash flow $-36.65M
- Revenue declining -22.70% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$698.80M$937.82M$806.78M$1.73B$1.73B
Net income$-559.02M$-626.60M$-363.30M$682.64M$-134.97M
EPS$8.58
Free cash flow$-509.11M$-279.04M$-181.94M$702.34M$-36.65M
Profit margin-80.00%-66.81%-45.03%39.44%39.40%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
PTCT$5.83B455.36.08.75.3+20.80%Hold
LLY$789.69B7810.010.05.06.5Strong Buy
JNJ$547.64B594.79.03.36.0-41.97%Buy
ABBV$351.47B634.08.04.75.0-24.92%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

PTC Therapeutics Inc trades at $64.55. representing a P/E of 8.19x trailing earnings. Our Smart Value Score of 45/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.22, it sits in the distress. TTM revenue stands at $1.73B. with profit margins at 39.40%. Our DCF model estimates intrinsic value at $89.55.

Frequently asked questions

What is PTC Therapeutics Inc's stock price?
PTC Therapeutics Inc (PTCT) trades at $64.55.
Is PTC Therapeutics Inc overvalued?
Smart Value Score 45/100 (Grade C, Sell). DCF value $89.55.
What is the price target of PTC Therapeutics Inc (PTCT)?
The analyst target price is $87.93, representing +36.2% upside from the current price of $64.55.
What is the intrinsic value of PTC Therapeutics Inc (PTCT)?
Based on our DCF model, intrinsic value is $89.55, a +20.8% margin of safety versus $64.55.
What is PTC Therapeutics Inc's revenue?
TTM revenue is $1.73B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
0.22 — distress.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio3.37x
ROE-7,740.00%
Beta0.55
50D MA$68.16
200D MA$66.15
Shares out0.08B
Float0.07B
Short ratio
Avg volume1.2M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years